Capricor extends PDUFA target date to Nov 22, 2026 for Deramiocel
Capricor received a three-month extension for the FDA review of its Deramiocel BLA to incorporate updated HOPE-3 data, reflecting continued regulatory engagement over a refined indication for Duchenne muscular dystrophy.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day